Physician
Modmd a Professional Corporation
Modmd a Professional Corporation was paid $962K by Medicaid between Dec 2021 and Dec 2024, across 9 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 59% of everything it billed.
33Billing provider infoMODMD A PROFESSIONAL CORPORATION
VENICE, CA 90291
VENICE, CA 90291
33aNPI1255904207assigned 07/19/2021
33bProvider typeEmergency Medicine Physician
28Total paid$962K
24GClaims23,053
24DCodes billed9
24AFirst – last monthDec 2021 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in California
Rank by total paid#222 of 988
Median peer was paid$32K
This provider vs. median30×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 93 | $3K | |
| 2022 | 1,716 | $62K | |
| 2023 | 16,132 | $647K | |
| 2024incomplete | 5,112 | $250K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 59% | 13,141 | 3,409 | $567K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 24% | 5,018 | 1,274 | $230K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 14% | 1,903 | 899 | $132K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.4% | 1,185 | 695 | $23K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 397 | 267 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 99 | 96 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 165 | 44 | $104.41 |
| 99001 | <1% | 1,123 | 306 | $50.00 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 22 | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDABBY, SHARON (CEO/MD)